A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined with Nivolumab Versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors

Protocol No
HBI-8000-303
Principal Investigator
Amy Harker-Murray
Phase
III
Summary
The purpose of this research study is to test if HBI-8000 is a safe and effective addition to the treatment for melanoma. A standard of care treatment for your cancer is Nivolumab. Researchers want to determine if HBI-8000 will help Nivolumab slow down the growth of melanoma, shrink the size of tumor(s), or extend life when you are treated with HBI-8000 and Nivolumab.
Description
To test if HBI-8000 is a safe and effective addition to the treatment for Melanoma
Participating Institutions
Froedtert Hospital
Status
SUSPENDED
Sub Category